Replies to post #5243 on Dendreon Corp fka DNDNQ

[walldiver]

Well, I'm on the record as stating that VITAL-1 gets stopped for futility at the first interim look, so I guess our views are diametrically opposite on this one. CEGE stated V-1 is 80% powered for statistical significance if the GVAX median survival beats the Taxotere MS by 33%...but this was assuming the Tax MS was 18.9 months, which was the figure for the entire ITT group in TAX327. It wasn't until three years later that SNY released the asymptomatic subgroup figure of 23.0 months.